Novo Nordisk A/S (NVO · NYSE)
NVO · MARKET VIEW
Market view · as of Aug 24, 2026
Revenue (TTM)
$329.43B
+2.1% YoY
Gross margin
82.0%
EPS (latest q)
$0.96
vs $0.82 est · beat
52-wk position
46.3%
-23.5% vs 52w high · -2.9% 1mo
Price (last ~year)
Novo Nordisk (NVO) has initiated the late-stage OASIS-5 clinical trial to test lower maintenance doses of its oral Wegovy weight-loss pill. The company reported TTM revenue of $329.43 billion and an 82.0% gross margin, though quarterly revenue declined to $78.49 billion for the period ending June 30, 2026. Shares are currently trading at $46.74, following a 20.6% year-over-year decrease in earnings.
Valuation
- Market cap
- $206.69B
- P/E
- 11.4
- PEG
- 3.162
- P/B
- 5.98
- P/S
- 0.627
- EV/EBITDA
- 9.64
- Beta
- 0.349
- Analyst target
- $47.48
Quality & returns
- Gross margin
- 82.0%
- Operating margin
- 42.5%
- Profit margin
- 35.3%
- ROE
- 59.8%
- ROA
- 18.7%
Price movement
- Last
- $46.74
- 1-month
- -2.9%
- 3-month
- +6.3%
- RSI (14)
- 51
- vs SMA200
- +3.7%
- 52-wk position
- 46.3% -23.5% vs high
Quarterly trajectory
Revenue by quarter (oldest → newest)
| Quarter | Revenue | Op income | Net income | EBITDA |
|---|---|---|---|---|
| 2026-06-30 | $78.49B | $27.06B | $20.99B | $38.68B |
| 2026-03-31 | $96.82B | $59.62B | $48.56B | $69.21B |
| 2025-12-31 | $79.14B | $31.74B | $26.89B | $39.75B |
| 2025-09-30 | $74.98B | $23.68B | $20.01B | $33.27B |
Recent news
- Neutral How cost and perception could reshape the GLP-1 market · 2026-08-21
- Neutral Novo Nordisk commences study for reduced Wegovy pill dosing · 2026-08-20
- Neutral Pursuing patient options, Novo kicks off trial testing smaller doses of Wegovy pill · 2026-08-20
- Neutral Eli Lilly, Novo Nordisk and Merck: Buy, Sell or Hold? · 2026-08-19
- Somewhat-Bullish Novo Nordisk Starts Testing Lower-Doses of Its Wegovy Weight-Loss Pills · 2026-08-19
- Somewhat-Bullish Novo Nordisk Begins New Study Testing Smaller Doses Of Blockbuster Wegovy – A Look At Some Key Highlights · 2026-08-19
Sources this view read
- fundamentals Company overview & valuation (Alpha Vantage OVERVIEW)
- filing Quarterly financial statements (Alpha Vantage INCOME/BALANCE/CASH)
- earnings Reported earnings history (Alpha Vantage EARNINGS)
- prices Adjusted daily prices (Alpha Vantage TIME_SERIES_DAILY_ADJUSTED)